Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.43 |
| ▸ | WNK1 | Q9H4A3 | 2/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2504177 | 0.85 | L3MBTL1 (0.42) | MAPTPKMKMT2AMEN1LMNA | |
| SCHEMBL2724020 | 0.80 | BCL2 (0.45) | BCL2 | |
| SCHEMBL31286225 | 0.79 | WNK1 (0.53) | ALDH3A1MAPTHCAR3WNK1MAPK1 | |
| SCHEMBL1700107 | 0.79 | WNK1 (0.53) | ALDH3A1MAPTHCAR3WNK1MAPK1 | |
| SCHEMBL30634506 | 0.79 | ABCC9 (0.39) | MAPTBCL2MAPK1PKMKMT2A | |
| SCHEMBL28102788 | 0.78 | MAPK1 (0.44) | ALDH3A1MAPTWNK1BCL2MAPK1 | |
| SCHEMBL31680953 | 0.77 | JAK3 (0.46) | — | |
| SCHEMBL1958971 | 0.77 | ALDH3A1 (0.56) | ALDH3A1MAPTHCAR3BCL2KMT2A | |
| SCHEMBL2408475 | 0.76 | MAPT (0.52) | MAPTMAPK1PKMKMT2AMEN1 | |
| SCHEMBL1957094 | 0.76 | KDM4E (0.55) | MAPTMAPK1PKMRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507211-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | claimed |
| EP-2507229-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | claimed |
| EP-2376197-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2011-10-19 | — | — | EP | claimed |
| WO-2011068560-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | claimed |
| WO-2011068561-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | claimed |
| WO-2010065824-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | WO | claimed |
| EP-2507211-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-2507229-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-2376197-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2376480-A2 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | Abbott Laboratories (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2011068561-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011068560-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2010065824-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065865-A2 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | WO | disclosed |